- Home
- CGAU vs FOLD Comparison
CGAU vs FOLD Comparison
Compare CGAU & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | FOLD |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CGAU | FOLD |
|---|---|---|
| Price | $18.33 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $16.67 | ★ $27.25 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.17 | $20.50 |
| Revenue Next Year | $13.62 | $18.59 |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.35 | $5.66 |
| 52 Week High | $21.17 | $14.50 |
Technical Indicators
Market Signals| Indicator | CGAU | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 74.18 |
| Support Level | $17.51 | $14.21 |
| Resistance Level | $20.18 | N/A |
| Average True Range (ATR) | 0.78 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 52.17 | 100.00 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.